Advertisement

Chemo Fog pp 33-36 | Cite as

The Economic Burden

  • Albert I. Wertheimer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 678)

Abstract

Not only is chemo fog a troublesome medical problem for the sufferers, but in addition it is the source of nearly $300 million in direct and indirect expense in the United States alone each year. And since it often persists for extended periods of time, the indirect costs, which stem mainly from lost productivity, continue to accumulate with another nearly $250 million added to the overall cost each year. This is not the highest economic burden for common diseases, but it is a significant amount that could be mostly avoided if biomedical scientists were to find a means to employ safer chemotherapeutic agents.

Keywords

Indirect Cost Direct Cost Vinca Alkaloid Total Direct Cost Diagnose Breast Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Apantaku LM. Breast cancer diagnosis and screening. American Family Physician 2000; 62(3):596–602 (Comment 605-606).PubMedGoogle Scholar
  2. 2.
    Breast cancer facts and figures, 2007–2008. American Cancer Society, p 2, Atlanta, 2007.Google Scholar
  3. 3.
    Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. Journal of the National Cancer Institute 2003; 95(3):190–197.PubMedCrossRefGoogle Scholar
  4. 4.
    Taillibert S, Voillery D, Bernard-Marty C. Chemobrain: is systemic chemotherapy neurotoxic? Current Opinion in Oncology 2007; 19(6):623–627.PubMedCrossRefGoogle Scholar
  5. 5.
    Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Current Opinion in Neurology 2007; 20(6):719–725.PubMedGoogle Scholar
  6. 6.
    Vardy J, Wefel JS, Ahles T et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology 2008; 19(4):623–629.PubMedCrossRefGoogle Scholar
  7. 7.
    Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncology Nursing Forum 2007; 34(5):981–994.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Albert I. Wertheimer
    • 1
  1. 1.Temple University School of PharmacyPhiladelphiaUSA

Personalised recommendations